Cenegermin

From WikiProjectMed
Jump to navigation Jump to search
Cenegermin
Names
Trade namesOxervate
Other namesCenegermin-bkbj, recombinant human nerve growth factor (rhNGF), human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer)[1]
Clinical data
Drug classNerve growth factor[2]
Main usesNeurotrophic keratitis[3]
Side effectsEye pain, increased tear production, eyelid pain[3]
Pregnancy
category
  • AU: B3
  • US: N (Not classified yet)
Routes of
use
Eye drop
External links
AHFS/Drugs.comMonograph
US NLMCenegermin
MedlinePlusa619001
Legal
License data
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Chemical and physical data
FormulaC583H908N166O173S8
Molar mass13267.15 g·mol−1

Cenegermin, sold under the brand name Oxervate, is a medication used to treat neurotrophic keratitis.[3] It is used in those with moderate or severe disease.[3] Use was not recommended by the United Kingdom.[2] It is used as an eye drop.[4]

Common side effects include eye pain, increased tear production, and eyelid pain.[3] Safety in pregnancy is unclear.[2] It is a recombinant form of nerve growth factor (NGF).[2]

Cenegermin was approved for medical use in Europe in 2017 and the United States in 2018.[3][4] In the United States 14 vials costs about 23,600 USD as of 2021.[5]

Medical uses

Dosage

It is used as 1 drop in the affected eye every 2 hours, 6 times per day.[3] It is used for 8 weeks.[3]

History

It was developed by Anabasis Pharma, Dompé Farmaceutici, and Ospedale San Raffaele.[6]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

Research

In addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma.[6]

See also

References

  1. World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1): 76. hdl:10665/330984.
  2. 2.0 2.1 2.2 2.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1210. ISBN 978-0857114105.
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "Oxervate". Retrieved 2 January 2022.
  4. 4.0 4.1 "Cenegermin-bkbj Monograph for Professionals". Drugs.com. Retrieved 2 January 2022.
  5. "Oxervate Prices and Oxervate Coupons - GoodRx". GoodRx. Retrieved 2 January 2022.
  6. 6.0 6.1 "Cenegermin - Dompe Farmaceutici - AdisInsight". adisinsight.springer.com. Retrieved 2020-06-05.
  7. New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.

External links

External sites:
Identifiers: